Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
05 Julho 2023 - 9:30AM
Business Wire
- Dr. Grossman brings over 20 years of drug development expertise
having held senior executive leadership positions in large and
small pharmaceutical companies leading the development and FDA
approval of numerous multi-billion dollar blockbuster drugs
addressing significant unmet medical needs particularly across CNS
disorders.
- Dr. Grossman held executive positions at Eli Lilly, Johnson
& Johnson, Bristol Myers Squibb, and Sunovion. He served as
President and Chief Medical Officer at Glenmark Pharmaceuticals
(BSE: 532296) as well as Chief Medical Officer at Mesoblast, Inc.
(NASDAQ: MESO).
- Dr. Grossman is Board-Certified in Psychiatry and a Fellow of
the American Psychiatric Association and was a Fellow at the
National Institutes of Health (NIH). He has held several academic
appointments and authored numerous scientific publications.
- Dr. Grossman will succeed Dr. Hepner, who is transitioning his
position due to personal reasons, but will remain committed to Coya
as Clinical and Strategic Advisor.
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the
“Company”), a clinical-stage biotechnology company developing
biologics intended to enhance Treg function, today announced the
appointment of Dr. Fred Grossman to its senior management team as
President and Chief Medical Officer.
Dr. Grossman will succeed Dr. Adrian Hepner in this role,
effective July 17th, 2023, and will leverage his over two decades
of clinical development expertise to guide and oversee all of
Coya’s development programs, including its lead asset, COYA 302,
for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Prior to joining Coya, Dr. Grossman held executive positions at
Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and
Sunovion. He also served as President and Chief Medical Officer at
Glenmark Pharmaceuticals, (BSE: 532296), a $1.5 Billion per annum
global pharmaceutical company based in India, overseeing
development of the entire pipeline including generics, complex
generics including 505(b)(2) candidates, and next-generation
biologics (including bi-specific antibodies). He also previously
served as Chief Medical Officer at Mesoblast, Inc. (NASDAQ: MESO),
developing allogeneic cellular therapies for inflammatory
diseases.
“We are grateful for Dr. Hepner’s leadership and excellence in
positioning Coya and look forward to having him continue to
collaborate with the Company in moving our assets forward. We also
welcome Dr. Grossman, who brings decades of clinical development
experience and successful execution,” stated Howard H. Berman,
Ph.D., CEO of Coya Therapeutics.
“Leading Coya’s development programs was a great honor. I am
proud of all the accomplishments we’ve made to date, and I continue
to be excited and very optimistic about the future of the Company.
This transition due to personal reasons gives me a fantastic
opportunity to continue supporting Coya’s strategy and its
development programs with the ultimate goal of delivering
innovative, safe and effective treatments to patients,” Dr. Hepner
said.
Dr. Grossman commented: “I look forward to building upon the
achievements of Dr. Hepner and the Team and contributing towards
advancing the development of Coya’s very innovative multi-modal
Treg pipeline addressing areas of significant unmet medical needs
across neurodegenerative and autoimmune disorders.”
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq:
COYA) is a clinical-stage biotechnology company developing
proprietary treatments focused on the biology and potential
therapeutic advantages of regulatory T cells (“Tregs”) to target
systemic inflammation and neuroinflammation. Dysfunctional Tregs
underlie numerous conditions including neurodegenerative,
metabolic, and autoimmune diseases, and this cellular dysfunction
may lead to a sustained inflammation and oxidative stress resulting
in lack of homeostasis of the immune system. Coya’s investigational
product candidate pipeline leverages multiple therapeutic
modalities aimed at restoring the anti-inflammatory and
immunomodulatory functions of Tregs. Coya’s lead therapeutic
programs includes Treg-enhancing biologics (COYA 300 Series product
candidates) COYA 301 and COYA 302, which are intended to enhance
Treg function and expand Treg numbers. COYA 301 is a cytokine
biologic for subcutaneous administration intended to enhance Treg
function and expand Treg numbers in vivo, and COYA 302 is a
biologic combination for subcutaneous and/or intravenous
administration intended to enhance Treg function while depleting T
effector function and activated macrophages. These two mechanisms
may be additive or synergistic in suppressing inflammation. For
more information about Coya, please visit
www.coyatherapeutics.com
Forward-Looking Statements
This press release contains “forward-looking” statements that
are based on our management’s beliefs and assumptions and on
information currently available to management. Forward-looking
statements include all statements other than statements of
historical fact contained in this presentation, including
information concerning our current and future financial
performance, business plans and objectives, current and future
clinical and preclinical development activities, timing and success
of our ongoing and planned clinical trials and related data, the
timing of announcements, updates and results of our clinical trials
and related data, our ability to obtain and maintain regulatory
approval, the potential therapeutic benefits and economic value of
our product candidates, competitive position, industry environment
and potential market opportunities. The words “believe,” “may,”
“will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,”
and similar expressions are intended to identify forward-looking
statements.
Forward-looking statements are subject to known and unknown
risks, uncertainties, assumptions and other factors including, but
not limited to, those related to risks associated with the impact
of COVID-19; the success, cost and timing of our product candidate
development activities and ongoing and planned clinical trials; our
plans to develop and commercialize targeted therapeutics; the
progress of patient enrollment and dosing in our preclinical or
clinical trials; the ability of our product candidates to achieve
applicable endpoints in the clinical trials; the safety profile of
our product candidates; the potential for data from our clinical
trials to support a marketing application, as well as the timing of
these events; our ability to obtain funding for our operations;
development and commercialization of our product candidates; the
timing of and our ability to obtain and maintain regulatory
approvals; the rate and degree of market acceptance and clinical
utility of our product candidates; the size and growth potential of
the markets for our product candidates, and our ability to serve
those markets; our commercialization, marketing and manufacturing
capabilities and strategy; future agreements with third parties in
connection with the commercialization of our product candidates;
our expectations regarding our ability to obtain and maintain
intellectual property protection; our dependence on third party
manufacturers; the success of competing therapies or products that
are or may become available; our ability to attract and retain key
scientific or management personnel; our ability to identify
additional product candidates with significant commercial potential
consistent with our commercial objectives; and our estimates
regarding expenses, future revenue, capital requirements and needs
for additional financing.
We have based these forward-looking statements largely on our
current expectations and projections about future events and trends
that we believe may affect our financial condition, results of
operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. Moreover, we
operate in a very competitive and rapidly changing environment, and
new risks may emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of
all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements
we may make. In light of these risks, uncertainties and
assumptions, the forward-looking events and circumstances discussed
herein may not occur and actual results could differ materially and
adversely from those anticipated or implied in the forward-looking
statements. Although our management believes that the expectations
reflected in our forward-looking statements are reasonable, we
cannot guarantee that the future results, levels of activity,
performance or events and circumstances described in the
forward-looking statements will be achieved or occur. We undertake
no obligation to publicly update any forward-looking statements,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230705959229/en/
Investor Contact David Snyder
david@coyatherapeutics.com
Hayden IR: James Carbonara (646)-755-7412 james@haydenir.com
Media Contact Anna Marie Imbordino
annamarie@quantum-corp.com 917-680-8765
Coya Therapeutics (NASDAQ:COYA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Coya Therapeutics (NASDAQ:COYA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024